{
  "_originalData": {
    "identity": {
      "bacteriumName": "Streptococcus pyogenes",
      "aliases": [
        "Beta hemolytic Strep",
        "Group A Strep",
        "Group B Strep",
        "Group C Strep",
        "Group F Strep",
        "Group G Strep"
      ],
      "lastUpdated": "2024-12-26",
      "clsiCategory": "Streptococcus spp. Beta-Hemolytic Group",
      "classification": {
        "gramStain": "Gram positive",
        "morphology": "cocci",
        "notes": [
          "Beta-hemolytic streptococci include the following Groups: A - S. pyogenes, B - S. agalactiae, C - S. equi, F, G - S. dysgalactiae"
        ]
      },
      "biochemicalTests": "Gram-positive cocci in chains, catalase â€“, beta-hemolytic, Bacitracin susceptible, PYR +, Lancefield Group A antigen +."
    },
    "clinicalProfile": {
      "summary": "Identification of Streptococcus pyogenes (Group A Streptococcus) in culture or by positive rapid test in a patient with pharyngitis. Positive tissue or blood culture of other beta-hemolytic streptococci is also relevant.",
      "clinicalSyndromes": [
        {
          "syndromeName": "Pharyngitis"
        },
        {
          "syndromeName": "Erysipelas"
        },
        {
          "syndromeName": "Impetigo"
        },
        {
          "syndromeName": "Necrotizing fasciitis"
        },
        {
          "syndromeName": "Bacteremia"
        },
        {
          "syndromeName": "Toxic shock syndrome"
        }
      ],
      "prognosisNotes": [
        "Post-infectious immune complications include acute rheumatic fever and acute glomerulonephritis."
      ]
    },
    "resistanceProfile": {
      "clinicalAlerts": [
        {
          "alertTitle": "Increasing Macrolide Resistance",
          "details": "There is increasing resistance to macrolide antibiotics."
        },
        {
          "alertTitle": "Low Clindamycin Resistance",
          "details": "Resistance to Clindamycin is <1% with standard testing."
        }
      ]
    },
    "treatment": {
      "drugsToAvoid": [
        {
          "drugOrClass": "fluoroquinolone",
          "condition": "Bacteremia and TSS",
          "reason": "high resistance rates or documented clinical failures."
        },
        {
          "drugOrClass": "sulfonamide (including TMP/SMX)",
          "condition": "Bacteremia and TSS",
          "reason": "high resistance rates or documented clinical failures."
        },
        {
          "drugOrClass": "doxycycline (or other tetracyclines)",
          "condition": "Bacteremia and TSS",
          "reason": "high resistance rates or documented clinical failures."
        }
      ],
      "regimens": [
        {
          "context": {
            "type": "Directed",
            "condition": "Group A Strep Pharyngitis",
            "patientPopulation": [
              "Adult"
            ]
          },
          "recommendations": [
            {
              "preference": "Primary",
              "drugs": [
                {
                  "drugName": "Penicillin G benzathine (Bicillin L-A)",
                  "dose": "1.2 million units",
                  "route": "IM",
                  "frequency": "x one dose"
                },
                {
                  "drugName": "Cephalexin",
                  "dose": "500 mg",
                  "route": "po",
                  "frequency": "bid",
                  "duration": "10 days"
                },
                {
                  "drugName": "Azithromycin",
                  "dose": "500 mg on day one, then 250 mg daily on days 2-5",
                  "route": "po"
                },
                {
                  "drugName": "Clindamycin",
                  "dose": "300 mg",
                  "route": "po",
                  "frequency": "tid",
                  "duration": "10 days"
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "Group A Strep Pharyngitis",
            "patientPopulation": [
              "Child"
            ]
          },
          "recommendations": [
            {
              "preference": "Primary",
              "drugs": [
                {
                  "drugName": "Pen VK",
                  "dose": "500 mg",
                  "route": "po",
                  "frequency": "bid",
                  "duration": "10 days"
                },
                {
                  "drugName": "Penicillin G benzathine combined with procaine penicillin G",
                  "dose": "900,000 units of benzathine Pen G with 300,000 units of procaine penicillin G",
                  "route": "IM",
                  "frequency": "x one dose",
                  "comments": "For Wt < 27 kg, to lessen pain"
                },
                {
                  "drugName": "Amoxicillin suspension",
                  "dose": "50 mg/kg/day",
                  "route": "po",
                  "frequency": "divided bid",
                  "comments": "more palatable and may be more efficacious due to better absorption"
                },
                {
                  "drugName": "Cephalexin",
                  "dose": "25-50 mg/kg/day",
                  "route": "po",
                  "frequency": "in 2 equally divided doses",
                  "duration": "10 days"
                },
                {
                  "drugName": "Azithromycin",
                  "dose": "12 mg/kg",
                  "route": "po",
                  "frequency": "once daily",
                  "duration": "5 days"
                },
                {
                  "drugName": "Clindamycin",
                  "dose": "7 mg/kg/dose",
                  "route": "po",
                  "frequency": "tid",
                  "duration": "10 days",
                  "comments": "wt < 70 kg"
                },
                {
                  "drugName": "Pen VK",
                  "dose": "25-50 mg/kg/day",
                  "route": "po",
                  "frequency": "div q6h",
                  "duration": "10 days"
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "Erysipelas/Cellulitis"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Sequential",
              "steps": [
                {
                  "step": 1,
                  "drugs": [
                    {
                      "drugName": "Penicillin G",
                      "dose": "2-4 million units",
                      "route": "IV",
                      "frequency": "q4-6h",
                      "comments": "until afebrile"
                    }
                  ]
                },
                {
                  "step": 2,
                  "drugs": [
                    {
                      "drugName": "Penicillin V-K",
                      "dose": "500 mg",
                      "route": "po",
                      "frequency": "qid"
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "notes": [
                "If skin rash allergy: Ceftriaxone 1 gm IV q24h or Cefazolin 1 gm IV q8h"
              ],
              "condition": "Skin rash allergy"
            },
            {
              "preference": "Alternative",
              "notes": [
                "If severe IgE-mediated allergy: Vancomycin 15 mg/kg IV q12h or Linezolid 600 mg IV/po bid; Clindamycin 600 mg IV q8h if no local resistance; Omadacycline"
              ],
              "condition": "Severe IgE-mediated allergy"
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "Bacteremia"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Concurrent",
              "drugs": [
                {
                  "drugName": "Clindamycin",
                  "dose": "600-900 mg",
                  "route": "IV",
                  "frequency": "q8h"
                },
                {
                  "drugName": "Penicillin G",
                  "dose": "4 million units",
                  "route": "IV",
                  "frequency": "q4h"
                }
              ]
            },
            {
              "preference": "Alternative",
              "notes": [
                "If no toxic shock and no in vitro resistance, Clindamycin alone is an option for penicillin allergy"
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "Toxic Shock Syndrome"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Concurrent",
              "drugs": [
                {
                  "drugName": "Penicillin G",
                  "dose": "4 million units",
                  "route": "IV",
                  "frequency": "q4h"
                },
                {
                  "drugName": "Clindamycin",
                  "dose": "600-900 mg",
                  "route": "IV",
                  "frequency": "q8h"
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Concurrent",
              "notes": [
                "Ceftriaxone 2 gm IV q24h + Clindamycin 600-900 mg IV q8h (instead of Penicillin G + Clindamycin)"
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Concurrent",
              "notes": [
                "If Clindamycin is not an option, combine Penicillin G with Linezolid 600 mg IV/po bid"
              ]
            }
          ]
        }
      ],
      "adjunctiveTherapies": [
        {
          "therapy": "IVIG",
          "condition": "Toxic Shock Syndrome",
          "details": "Some add IVIG, 1 gm/kg on day 1, then 0.5 gm/kg on days 2 and 3"
        }
      ]
    },
    "additionalInformation": {
      "drugSpecificPearls": [
        {
          "drugName": "TMP/SMX",
          "pearl": "TMP/SMX 1-2 DS bid may be effective for uncomplicated cellulitis in out-patients without medical co-morbidities."
        },
        {
          "drugName": "Fluoroquinolones",
          "pearl": "Fluoroquinolones may be effective for uncomplicated skin infections but not for pharyngitis or invasive infection."
        },
        {
          "drugName": "Clindamycin",
          "pearl": "Clindamycin is felt to be superior to Penicillin because its antibacterial effect is not affected by inoculum size or the stage of bacterial growth."
        }
      ],
      "guidelineReferences": [
        {
          "summaryOrNote": "Susceptibilities of non-Group A streptococci (Groups B, C, F, G) are similar to Group A, and treatment is also similar."
        }
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.356Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Streptococcus pyogenes"
    },
    "aliases": {
      "sources": [
        "identity.aliases"
      ],
      "value": [
        "Beta hemolytic Strep",
        "Group A Strep",
        "Group B Strep",
        "Group C Strep",
        "Group F Strep",
        "Group G Strep"
      ]
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2024-12-26"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Gram positive",
        "morphology": "cocci",
        "notes": [
          "Beta-hemolytic streptococci include the following Groups: A - S. pyogenes, B - S. agalactiae, C - S. equi, F, G - S. dysgalactiae"
        ]
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "Identification of Streptococcus pyogenes (Group A Streptococcus) in culture or by positive rapid test in a patient with pharyngitis. Positive tissue or blood culture of other beta-hemolytic streptococci is also relevant.",
      "clinicalSyndromes": [
        {
          "syndromeName": "Pharyngitis"
        },
        {
          "syndromeName": "Erysipelas"
        },
        {
          "syndromeName": "Impetigo"
        },
        {
          "syndromeName": "Necrotizing fasciitis"
        },
        {
          "syndromeName": "Bacteremia"
        },
        {
          "syndromeName": "Toxic shock syndrome"
        }
      ],
      "prognosisNotes": [
        "Post-infectious immune complications include acute rheumatic fever and acute glomerulonephritis."
      ]
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "clinicalAlerts": [
        {
          "alertTitle": "Increasing Macrolide Resistance",
          "details": "There is increasing resistance to macrolide antibiotics."
        },
        {
          "alertTitle": "Low Clindamycin Resistance",
          "details": "Resistance to Clindamycin is <1% with standard testing."
        }
      ]
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": [
        {
          "regimenId": "modern-2-0-0",
          "extractedFrom": "treatment.regimens[2].recommendations[0].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Erysipelas/Cellulitis",
            "severity": "unknown",
            "patientFactors": {
              "population": []
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Penicillin G",
              "dose": "2-4 million units",
              "route": "IV",
              "frequency": "q4-6h",
              "comments": "until afebrile",
              "originalText": "Penicillin G 2-4 million units IV q4-6h"
            }
          ]
        },
        {
          "regimenId": "modern-2-0-1",
          "extractedFrom": "treatment.regimens[2].recommendations[0].steps[1]",
          "context": {
            "type": "directed",
            "condition": "Erysipelas/Cellulitis",
            "severity": "unknown",
            "patientFactors": {
              "population": []
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Penicillin V-K",
              "dose": "500 mg",
              "route": "po",
              "frequency": "qid",
              "originalText": "Penicillin V-K 500 mg po qid"
            }
          ]
        }
      ]
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile",
      "laboratory"
    ],
    "value": {}
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}